Telomeres and telomerase in normal and leukemic hematopoietic cells

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1001-1004

  Engelhardt, Monika ^a   Wäsch, Ralph ^a   Guo, Yalin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

AML; Genomic instability; MDS; Telomerase; Telomere

Indexed keywords

PROTECTION OF TELOMERES 1 PROTEIN; PROTEIN; TANKYRASE; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD SAMPLING; BONE MARROW; CARCINOGENESIS; CHROMOSOME; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; GENETIC STABILITY; GENOME ANALYSIS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RISK ASSESSMENT; TELOMERE;

EID: 3843091665     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.01.015     Document Type: Article

References (39)

1. Guo Y., Follo M., Geiger K., Lubbert M., Engelhardt M. Side-population cells from different precursor compartments. J. Hematother. Stem Cell Res. 12:2003;71-82
2. Guo Y., Lubbert M., Engelhardt M. CD34-hematopoietic stem cells: current concepts and controversies. Stem Cells. 21:2003;15-20
3. Elwood N.J. Telomere biology of human hematopoietic stem cells. Cancer Control. 11(2):2004;77-85
4. Zakian V.A. Telomeres: beginning to understand the end. Science. 270:1995;1601-1607
5. Harley CB. Telomeres and aging. In: Blackburn EHG, Greider CW, editors. Telomeres. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1995, p. 247-65.
6. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., et al. Mammalian telomeres end in a large duplex loop. Cell. 97:1999;503-514
7. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015
8. Weng N.P., Levine B.L., June C.H., Hodes R.J. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11091-11094
9. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 361:2003;393-395
10. Collins K. Telomere maintenance and disease. Lancet. 362:2003;983-988
11. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352
12. Ramirez R.D., Morales C.P., Herbert B.S., Rohde J.M., Passons C., Shay J.W., et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev. 15:2001;398-403
13. Henson J.D., Neumann A.A., Yeager T.R., Reddel R.R. Alternative lengthening of telomeres in mammalian cells. Oncogene. 21:2002;598-610
14. van Steensel B., de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature. 385:1997;740-743
15. van Steensel B., Smogorzewska A., de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 92:1998;401-413
16. Karlseder J., Broccoli D., Dai Y., Hardy S., de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1999;1321-1325
17. Loayza D., de Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 424:2003;1013-1018
18. Karlseder J., Smogorzewska A., de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 295:2002;2446-2449
19. Brummendorf T.H., Holyoake T.L., Rufer N., Barnett M.J., Schulzer M., Eaves C.J., et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 95:2000;1883-1890
20. Engelhardt M., Silver R.T., Drullinsky P., Mackenzie K., Moore M.A.S. Telomerase activity and telomere length primitive hematopoietic cells of acute and chronic leukemias at baseline and after ex vivo expansion. Cancer Res. 60:2000;610-617
21. Adamson D.J.A., King D.J., Haites N.E. Significant telomere shortening in childhood leukemia. Cancer Genet. Cytogenet. 61:1992;204-206
22. Ohyashiki J.H., Sashida G., Tauchi T., Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 21:2002;680-687
23. Shay J.W., Werbin H., Wright W.E. Telomeres and telomerase in human leukemias. Leukemia. 10:1996;1255-1261
24. Engelhardt M., Ozkaynak M.F., Drullinsky P., Sandoval C., Tugal O., Jayabose S., et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia. 12:1998;13-24
25. Franco S., Ozkaynak M.F., Sandoval C., Tugal O., Engelhardt M., Moore M.A.S. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia. 17:2003;401-410
26. Ohyashiki J.H., Ohyashiki K., Fujimura T., Kawakubo K., Shimamoto T., Iwabuchi A., et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res. 54:1994;3557-3560
27. Boultwood J., Fidler C., Kusec R., Rack K., Elliott P.J., Atoyebi O., et al. Telomere length in myelodysplastic syndromes. Am. J. Hematol. 56:1997;266-271
28. Engelhardt M., Kumar R., Albanell J., Pettengell R., Han W., Moore M.A.S. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 90:1997;182-193
29. Martens U.M., Brass V., Sedlacek L., Pantic M., Exner C., Guo Y., et al. Telomere maintenance in human B lymphocytes. Br. J. Haematol. 119:2002;810-818
30. Wynn R.F., Cross M.A., Hatton C., Will A.M., Lashford L.S., Dexter T.M., et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 351:1998;178-181
31. Rufer N., Brummendorf T.H., Chapuis B., Helg C., Lansdorp P.M., Roosnek E. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood. 97:2001;575-577
32. Engelhardt M., Finke J. Does telomere shortening count? Blood. 98:2001;888-889
33. Thornley I., Sutherland R., Wynn R., Nayar R., Sung L., Corpus G., et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood. 99:2002;2387-2396
34. Legare R.D., Gribben J.G., Maragh M., Hermanowski-Vosatka A., Roach S., Tantravahi R., et al. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am. J. Hematol. 56:1997;45-51
35. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 95:2000;3273-3279
36. Nichols G., de Castro K., Wei L.X., Griffin M., Lin N., Oratzi A., et al. Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia. 16:2002;1673-1679
37. Podesta M., Piaggio G., Frassoni F., Pitto A., Mordini N., Bregante S., et al. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 19:1997;1011-1017
38. Awaya N., Baerlocher G.M., Manley T.J., Sanders J.E., Mielcarek M., Torok-Storb B., et al. Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure? Biol. Blood Marrow Transplant. 8:2002;597-600
39. Sieglova Z, Zilovcova S, Cermak J et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis. Leukemia Res, doi:10.1016/j.leukres.2003.11.020, this issue.